LAVA Therapeutics N.V. reported unaudited condensed consolidated earnings results for the three months ended March 31, 2021. For the period, the company reported total revenue of EUR 921,000. Operating loss was EUR 16,233,000 against EUR 3,617,000 a year ago. Loss for the period was EUR 16,574,000 against EUR 3,678,000 a year ago. Basic and diluted loss per share was EUR 10.19 against EUR 8.22 a year ago. Total comprehensive loss for the period was EUR 16,085,000 against EUR 3,678,000 a year ago.